·¬ΗΡΚΣΖ΅

Meeting Coverage

IGCS

International Gynecologic Cancer Society

Bispecific Antibody Shows Clinical Activity in Recurrent Ovarian Cancer

Alone or combined with a PD-1 inhibitor, ubamatamab showed promise in phase I trial

IGCS over a photo of COEX Convention & Exhibition Center in Seoul, South Korea.

Latest IGCS Meeting Coverage

T-DXd Tied to Encouraging Survival in HER2-Expressing Gyn Cancers

More responses, longer OS in subset with the highest levels of HER2 expression

November 7, 2023
Sexual Health Suffered After Radical Hysterectomy for Early Cervical Cancer

Compared with simple hysterectomy, analysis shows more sexual toxicities, worse quality of life

November 7, 2023
Mixed Results for Tiragolumab/Atezolizumab Combo in PD-L1+ Recurrent Cervical Cancer

Overall response beats historical benchmark, but misses significance target

November 6, 2023
RAF/MEK and FAK Inhibitor Combo Effective in Low-Grade Serous Ovarian Cancer

Impressive overall response rate with avutometinib-defactinib in RAMP 201 trial

November 5, 2023
Maintenance Selinexor May Boost PFS in TP53 Wild-Type Advanced Endometrial Cancer

Particularly strong PFS signal seen in patients that were mismatch repair proficient

November 5, 2023
FDA's Power Morcellator Warning Tied to Drop in Distant Leiomyosarcomas

Local and regional illness remained unchanged

October 4, 2022
Pandemic Led to Surgical Delays in Gynecologic Cancers, and Worse Outcomes

One in five patients experienced changes in their care plan

October 4, 2022
Adding Chemo Not Better for Recurrent Endometrial Cancer

Trial suggests radiation therapy alone remains standard of care for pelvic-only recurrences

October 3, 2022
Durvalumab-CRT Pairing Disappoints in Locally Advanced Cervical Cancer

Still, CALLA trial findings "will inform future strategies to improve treatment," researcher says

October 2, 2022
Rucaparib a Winner for PFS, But Not for OS, in Recurrent Ovarian Cancer

PARP inhibitor still has value as maintenance therapy, ARIEL3 investigator says

October 1, 2022
'Potential Detrimental Effect' With Fourth-Line Olaparib in Ovarian Cancer

Post-hoc data from SOLO3 show diverging results based on prior lines of therapy

September 30, 2022

Videos

IGCS Future Focus
November 2023
IGCS Video Pearls
November 2023